• We are dedicated to
    the future of clinical development
    and to every life it saves.

    Learn more about why we do what we do, and what we can do for you. Click to read our story.

Social Media

See the latest interactions from our social media


Learn more about real world data and #clinicaltrials. PRA featured in @acrohealth video series. http...

View Post

Featured News

Read the latest updates from our PR department

WuXi PharmaTech and PRA Health Sciences Restructure Relationship in China

8 December 2015, Shanghai, China and Raleigh, NC – WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading open-access R&D capability and technology platform company serving the...

PRA Health Sciences Expands Operations in Singapore

17 November 2015, Raleigh, NC – PRA Health Sciences (PRA) (NASDAQ: PRAH) is pleased to announce that it is relocating to a new office in Singapore to support its expanded operations in the...

PRA Health Sciences, inc. Reports third quarter 2015 results and provides updated 2015 guidance

• $345.1 million of service revenue in the third quarter; 12% constant currency growth compared to the third quarter of 2014
• $66.6 million of Adjusted EBITDA in the third quarter; 42%...

Read More >

Media Resources

Explore the latest resources uploaded to our media library

Sign Up for PRA's Industry Watch

Brought to you by PRA Health Sciences. A Bi-Weekly Industry Watch Newsletter

CASE STUDY: PRA Feasibility Leads To Unique Enrollment Strategy

PRA recently performed a feasibility study to identify investigators who see patients with a rare neuromuscular autoimmune disease and who have the capability to perform a Phase II clinical trial.


PRA Health Sciences provides our clients with innovative solutions for CNS (neurology, psychiatry, and pain) drug development. Our work spans from early phase development to NDA and MAA submissions...

CASE STUDY: PRA Teamwork Demonstrates Vision

A large pharmaceutical client selected PRA to conduct 2 Phase III epilepsy studies in India, Eastern and Western Europe, and Australia. PRA’s project teams surpassed recruitment goals and achieved timely site activations despite administrative delays and tough competition for volunteers.


Find out what's happening next on PRA's event schedule

March 23 - March 24

In 2016, BioPharma Asia’s conference format is refreshed to drive deeper into the core of the various functions in the biopharmaceutical value chain. Each session’s topics are crafted to focus on a key trend in Asia’s biopharma industry, be it trials, manufacturing, supply or biotech investments. Speakers: Scott Schliebner (Vice President of Scientific Affairs – […]

June 5 - June 7

Opioids are effective tools when used properly in the management of pain. They are cost effective and allow increased numbers of patients to return to active productive lives in society. Yet, while opioids have been with us for over 4000 years, the landscape of opioid therapies is rapidly evolving. Federal and state regulations are swiftly […]

Read More >